Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21026049 | 0.94 | MAPT (0.32) | MEN1KMT2A | |
| SCHEMBL25704315 | 0.93 | MEN1 (0.41) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL21214834 | 0.93 | MEN1 (0.41) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL20234681 | 0.91 | CES2 (0.34) | MEN1KMT2AKDM4ECYP2C19 | |
| SCHEMBL21025933 | 0.90 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL20372471 | 0.89 | MEN1 (0.34) | MEN1KMT2AKDM4EALDH1A1CYP2C19 | |
| SCHEMBL18592238 | 0.87 | KDM4E (0.40) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL21025857 | 0.83 | MEN1 (0.34) | MEN1KMT2AKDM4EPOLBTDP1 | |
| SCHEMBL20234763 | 0.81 | MEN1 (0.38) | MEN1KMT2AKDM4ETDP1ALDH1A1 | |
| SCHEMBL20443168 | 0.81 | MEN1 (0.30) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11220515-B2 | Imide-based modulators of proteolysis and associated methods of use | YALE UNIVERSITY (US) | 2022-01-11 | — | — | US | disclosed |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | YALE UNIVERSITY | 2019-08-01 | — | — | US | disclosed |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11220515-B2 | Imide-based modulators of proteolysis and associated methods of use | CRBN, MDM2, UBE2N | MEN1 1077/4885KMT2A 1660/4885KDM4E 498/4885 |
| US-20180099940-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | MEN1 1676/4885KMT2A 1478/4885KDM4E 713/4885 |
| US-20190233433-A1 | IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE | CRBN, MDM2, UBE2N | MEN1 1077/4885KMT2A 1660/4885KDM4E 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.